BAJAJ BROKING

Notification close image
No new Notification messages
card image
Shanti Gold International IPO is Open!
Apply for the Shanti Gold International IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Cipla Q1 FY25–26 Results: Net Profit Rises to ₹1,291.61 Crore, Total Income at ₹7,216.03 Crore

Cipla Q1 FY25–26 Results: Net Profit Rises to ₹1,291.61 Crore, Total Income at ₹7,216.03 Crore

Synopsis:


Cipla recorded ₹1,291.61 crore in net profit and ₹6,957.47 crore in revenue for Q1 FY25–26. Performance was driven by strong pharmaceutical growth and improved contribution from new ventures, maintaining a stable financial trajectory with consistent earnings momentum.

Key Highlights

  • Revenue from operations: ₹6,957.47 crore

  • Total income: ₹7,216.03 crore

  • Profit before tax: ₹1,769.93 crore

  • Net profit (after tax): ₹1,291.61 crore

  • Basic earnings per share (EPS): ₹16.07

  • Segment revenue – Pharmaceuticals: ₹6,579.42 crore

  • Segment revenue – New ventures: ₹443.70 crore

  • Segment result – Pharmaceuticals: ₹1,727.22 crore

  • Segment result – New ventures: ₹56.76 crore

CIPLA LTD

Trade

1532.544.59 (2.99 %)

Updated - 25 July 2025
1553.70day high
DAY HIGH
1469.00day low
DAY LOW
5226395
VOLUME (BSE)

Quarterly Performance: Cipla Q1 FY25–26

Cipla recorded a steady quarterly performance driven by a strong pharmaceutical segment and growing contribution from new business initiatives. Operational revenue remained stable, while expenses were effectively managed across verticals.

Financial Summary – ₹ in crore

Particulars

Q1 FY26

Q4 FY25

Q1 FY25

Revenue from operations

6,957.47

6,729.69

6,693.94

Other income

258.56

289.46

160.19

Total income

7,216.03

7,019.15

6,854.13

Total expenses

5,446.10

5,514.85

5,242.77

Profit before share of associates and tax

1,769.93

1,504.30

1,611.36

Tax expense (net)

477.88

279.28

365.90

Net profit for the period

1,291.61

1,214.14

1,275.46

Total comprehensive income

1,373.02

1,266.01

1,246.20

Basic earnings per share (₹2 face value)

₹16.07

₹15.13

₹14.58

Segment Highlights

1. Revenue by Segment

Cipla operates through two major reporting segments: Pharmaceuticals and New Ventures.

Segment

Q1 FY26 Revenue (₹ Cr)

Q1 FY25 Revenue (₹ Cr)

Pharmaceuticals

6,579.42

6,389.30

New Ventures

443.70

353.98

Total Revenue

7,023.12

6,743.28

Inter-segment adj.

65.65

49.34

Net Revenue

6,957.47

6,693.94

2. Segment Results

Segment

Q1 FY26 Result (₹ Cr)

Q1 FY25 Result (₹ Cr)

Pharmaceuticals

1,727.22

1,630.64

New Ventures

56.76

(1.33)

Finance Costs

14.05

17.95

PBT (Pre-tax)

1,769.93

1,611.36

The pharmaceutical business remains the primary contributor to revenue and profit, while new ventures returned to profitability this quarter.

Management Commentary 

Commenting on the Q1 results Umang Vohra, MD and Global CEO of Cipla quoted “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy.”

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Source - Q1 FY25-26 Quarterly Results Uploaded on BSE dated 25 July 2025

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|